Berkeley settlement
This article was originally published in The Tan Sheet
Executive Summary
A court case filed in the district court of Dallas County, Texas precludes the five companies owned by Steven Warshak - including Berkeley Premium Nutraceuticals - from fraudulently marketing 15 dietary supplements in the state. The banned supplements include male enhancement supplement Enzyte, noted for its "Smiling Bob" commercials. The case also stops deceptive "free trial" offers for the dietary supplements. Under the Feb. 1 settlement, Warshak will pay the state of Texas $350,000 in civil penalties and attorneys' fees. In September 2006 a federal grand jury indicted Berkeley Premium Nutraceuticals, Warshak, his mother and five additional co-conspirators on a total of 112 criminal charges (1"The Tan Sheet," Sept. 25, 2006, In Brief)...
You may also be interested in...
“Crying” Bob
A federal grand jury indicted Berkeley Premium Nutraceuticals, the company's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges Sept. 20. Warshak engaged in conspiracy to commit mail, wire and bank fraud, money laundering, conspiracy to obstruct proceedings before FTC and other criminal acts, U.S. Attorney for the Southern District of Ohio Gregory Lockhart alleges. Warshak, et al., defrauded consumers of more than $100 mil., according to Lockhart. If convicted, the defendants are expected to forfeit assets including several parcels of land, vehicles, and the contents of numerous bank and investment accounts, according to the filing. Berkeley, marketer of male enhancement supplement Enzyte, settled with the Attorney Generals of six states in March for $2.5 mil. (1"The Tan Sheet" March 6, 2006, p. 8). Earlier this month, the Cincinnati, Ohio-based firm issued a press release asserting they had reduced consumer complaints by 90% (2"The Tan Sheet" Sept. 11, 2006, In Brief)....
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.